EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Pembrolizumab and Sarcoma: A meta-analysis

Rebaz M. Ali, Sami S. Omar, Shalaw H. Abdalla, Fattah H. Fattah, Shnya R. Hamalaw, Hussein M. Hamasalih, Ayman M. Mustafa, Sanaa O. Karim, Yousif M. Mahmood, Meer M. Abdulkarim, Ahmed G. Hamasaeed, Dana O. Karim und 1 weitere

Judi Clinical Journal · 2025

DOI: 10.70955/jcj.2025.6 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Judi Clinical Journal, 2025. Verfasst von Rebaz M. Ali und 12 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety profile of this treatment as monotherapy or in combination with other drugs for the treatment of sarcomas.

Methods

A literature search was conducted across Google Scholar, PubMed/MEDLINE, and EMBASE from February 15th to April 15th. Eligible studies were clinical trials that reported efficacy or outcomes of pembrolizumab in sarcoma patients, either alone or in combination with other drugs. In contrast, those lacking sufficient data or not meeting trial criteria were excluded.

Results

Ten clinical trials met the eligibility criteria, including 419 sarcoma patients (53.7% male; median age 55.4). Pembrolizumab was administered either as monotherapy in 23% of cases or in combination with other agents in 77% of cases. The progressive disease rate was 83% with monotherapy and 36% with combination therapy. Objective response rates varied, with the highest observed in the pembrolizumab plus talimogene laherparepvec combination (35%) and the lowest in pembrolizumab monotherapy (ranging from 0% to 11.2%). Median progression-free survival ranged from 1.4 (Pembrolizumab + Cyclophosphamide) to 7.8 months (Pembrolizumab + Lenvatinib in undifferentiated pleomorphic sarcoma). Combination therapy was associated with significantly better tumor response (

Zitieren

APA

Ali, R. M., Omar, S. S., Abdalla, S. H., Fattah, F. H., Hamalaw, S. R., Hamasalih, H. M., Mustafa, A. M., Karim, S. O., Mahmood, Y. M., Abdulkarim, M. M., Hamasaeed, A. G., Karim, D. O., & Ahmad, A. D. (2025). Pembrolizumab and Sarcoma: A meta-analysis. Judi Clinical Journal. https://doi.org/10.70955/jcj.2025.6

Vancouver

Ali RM, Omar SS, Abdalla SH, Fattah FH, Hamalaw SR, Hamasalih HM, et al. Pembrolizumab and Sarcoma: A meta-analysis. Judi Clinical Journal. 2025. doi:10.70955/jcj.2025.6

BibTeX
@article{Ali2025,
  author = {Ali, Rebaz M. and Omar, Sami S. and Abdalla, Shalaw H. and Fattah, Fattah H. and Hamalaw, Shnya R. and Hamasalih, Hussein M. and Mustafa, Ayman M. and Karim, Sanaa O. and Mahmood, Yousif M. and Abdulkarim, Meer M. and Hamasaeed, Ahmed G. and Karim, Dana O. and Ahmad, Abdullah D.},
  title = {Pembrolizumab and Sarcoma: A meta-analysis},
  journal = {Judi Clinical Journal},
  year = {2025},
  doi = {10.70955/jcj.2025.6}
}
Kostenlos starten →